Why the study?
Does CYP2C19*2 genotype explain the variability in on-treatment platelet reactivity in clopidogrel pretreated patients undergoing elective coronary stenting?
Population
1069 clopidogrel pretreated patients undergoing elective coronary stenting
Design
Cohort
Authors
Loading...
CYP2C19*2 testing alone may not predict clopidogrel response; leaves open contributions of other genetic and clinical factors to platelet reactivity variability.
Does CYP2C19*2 genotype explain the variability in on-treatment platelet reactivity in clopidogrel pretreated patients undergoing elective coronary stenting?
While the CYP2C19*2 loss-of-function polymorphism is associated with high on-treatment platelet reactivity, it explains only a modest portion of the interindividual variability in clopidogrel response.
Bouman et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: